Cox C E, Holloway W J, Geckler R W
Department of Urology, University of Tennessee College of Medicine, Memphis 38163, USA.
Clin Infect Dis. 1995 Jul;21(1):86-92. doi: 10.1093/clinids/21.1.86.
The safety and efficacy of meropenem and imipenem/cilastatin were compared in the treatment of hospitalized patients with complicated urinary tract infections (UTIs) in a prospective, multicenter, open, parallel-group trial. Patients were randomized to receive 500-mg intravenous doses of either meropenem every 8 hours (n = 116) or imipenem/cilastatin every 6 hours (n = 119). Data from 95 patients given meropenem and 82 patients given imipenem/cilastatin were included in the evaluation of efficacy. Meropenem produced satisfactory clinical and bacteriologic responses in 99% and 90% of cases, respectively. These results were similar to those obtained with imipenem/cilastatin, which produced clinical improvement in 99% of cases and bacteriologic improvement in 81%. Two patients given meropenem and five patients given imipenem/cilastatin developed superinfections. The rate of relapse was similar in the two groups. Patients who received meropenem had fewer drug-related adverse reactions than did recipients of imipenem/cilastatin (8% vs. 19%). The results of this study demonstrate that meropenem is a safe and effective alternative to imipenem/cilastatin in the treatment of hospitalized patients with complicated UTIs.
在一项前瞻性、多中心、开放、平行组试验中，比较了美罗培南与亚胺培南/西司他丁治疗住院复杂性尿路感染（UTI）患者的安全性和有效性。患者被随机分为两组，一组每8小时静脉注射500mg美罗培南（n = 116），另一组每6小时静脉注射亚胺培南/西司他丁（n = 119）。对95例接受美罗培南治疗的患者和82例接受亚胺培南/西司他丁治疗的患者的数据进行疗效评估。美罗培南分别在99%和90%的病例中产生了满意的临床和细菌学反应。这些结果与亚胺培南/西司他丁的结果相似，亚胺培南/西司他丁在99%的病例中产生了临床改善，在81%的病例中产生了细菌学改善。两名接受美罗培南治疗的患者和五名接受亚胺培南/西司他丁治疗的患者发生了二重感染。两组的复发率相似。接受美罗培南治疗的患者比接受亚胺培南/西司他丁治疗的患者药物相关不良反应更少（8%对19%）。本研究结果表明，在治疗住院复杂性UTI患者时，美罗培南是亚胺培南/西司他丁的一种安全有效的替代药物。
